Skip to main content
editorial
. 2019 Mar 1;10(18):1662–1663. doi: 10.18632/oncotarget.26718

Figure 1. Novel mechanism of adaptive resistance towards BRAF inhibitors in melanoma.

Figure 1

BRAF inhibitor treatment leads to an increased STAT3 activation. STAT3 promotes the expression of SOX2 and SOX2 then induces the expression of CD24. CD24 in turn promotes Src and STAT3 activity most likely due to a change in the lipid raft composition favoring cancer cell survival. Thus, inhibitors targeting STAT3 or Src can help to overcome this mechanism of adaptive resistance.